Quantitative evaluation of [18F] flutemetamol PET for patients suspected of Alzheimer's dementia; a multicenter study

Quantitative evaluation of PET imaging using [18F] flutemetamol injection solution for patients with cognitive impairment suspected of Alzheimer's dementia; a multicenter study - Quantitative Flutemetamol PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180321

Enrollment

100

Registered

2019-03-18

Start date

2019-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease Alzheimer Cognitive Impairment

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with cognitive impairment suspected of AD, regardless of age and gender. Patients suspected of having AD based on NIA-AA or DSM-V Patients who underwent brain MRI (T1 weighted image (3D imaging is preferable), T2 weighted image, FLAIR image) up to 60 days before registration Patients who obtain consent from the patients themselves or from the legally acceptable representative in writing

Exclusion criteria

Exclusion criteria: Cognitively normal patients Patients with mild cognitive impairment (MCI) Patients with brain lesions (brain tumor, vascular malformation, cortical infarction, etc.) in brain MRI Patients with severe allergy to alcohol or polysorbate 80 (Solubilizer) Pregnant women, lactating women and those who may be pregnant Patients who are judged inappropriate by chief researchers

Design outcomes

Primary

Measure	Time frame
Qualitative evaluation and quantitative evaluation index of the amyloid PET image	—

Secondary

Measure	Time frame
Diagnostic confidence before and after amyloid PET	—

Contacts

Public ContactHiroshi Matsuda

Research Institute for Neuroscience

matsudah@ncnp.go.jp+81-24-934-5610

Outcome results